HOME >> BIOLOGY >> NEWS
Drug lowers inflammatory markers associated with risk for heart attack

The trial included MI patients who carry at-risk variants in the FLAP gene or in the leukotriene A4 hydrolase gene. Of 268 patients screened, 191 were carriers of at-risk variants in FLAP (87 percent) or leukotriene A4 hydrolase (13 percent). Individuals were enrolled in April 2004 and were followed up by designated cardiologists from the Landspitali University Hospital in Iceland until September 2004. Patients were first randomized to receive 250 mg/d of DG-031, 500 mg/d of DG-031, 750 mg/d of DG-031, or placebo. After a 2-week washout period, patients received DG-031 if they had received placebo first or placebo if they had received DG-031 first. Treatment periods lasted for 4 weeks.

The researchers found that levels of several biomarkers linked to arterial inflammation and risk of MI decreased. In response to 750 mg/d of DG-031, production of leukotriene B4 was significantly reduced by 26 percent and myeloperoxidase was significantly reduced by 12 percent. The higher 2 doses of DG-031 produced a nonsignificant reduction in C-reactive protein (16 percent) at 2 weeks. However, there was a more pronounced reduction (25 percent) in C-reactive protein at the end of the washout period that was significant and persisted for another 4 weeks thereafter. An 8-day, open-label follow-up study with 75 patients with the same genetic and disease profile as in the Phase IIa was conducted to further examine the effect of DG031 on CRP and myeloperoxidase. The results of this study showed that the 750mg/d dose of DG031, when administered as 250 mg 3 times daily resulted in a 38 percent reduction in CRP levels, as well as a 31 percent reduction in myeloperoxidase levels measured 6 hours after dosing on day 8. In both studies, the FLAP inhibitor DG-031 was well-tolerated and was not associated with any serious adverse events.

"When taken together, the data from our MI gene-isolation study and the clinical trial reported herein show that DG-031 is a safe and w
'"/>

Contact: Edward Farmer
edward.farmer@decode.is
354-570-2819
JAMA and Archives Journals
10-May-2005


Page: 1 2 3 4

Related biology news :

1. Columbine flowers develop long nectar spurs in response to pollinators
2. Nondanger signal lowers immune reactions
3. Plants with male and bisexual flowers on the same plant are better mothers
4. Flowers shape themselves to guide their pollinators to the pollen
5. Orange juice beverage fortified with plant sterols lowers indicators of heart disease risk
6. How did bilaterally symmetric flowers evolve from radially symmetric ones?
7. Genetic snooze button governs timing of spring flowers
8. Wild bees and the flowers they pollinate are disappearing together
9. Low-to-moderate prenatal alcohol exposure lowers IQ at age 10
10. How flowers changed the world a new book by Field Museum scientist
11. Lots of flowers and trees, not enough birds and bees

Post Your Comments:
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
(Date:4/28/2015)... April 28, 2015  US-Australian drug discovery company, Novogen ... it received a letter from NASDAQ informing it that ... 5550(b) (Listing Rule). In November 2014, ... the Company to submit a plan to regain compliance ... minimum of $2,500,000 in stockholders, equity as of June ...
(Date:4/28/2015)... 28, 2015 IMS is releasing ... it to the web and provide greater accessibility ... friendly reporting metrics increase data warehouse’s utility; plus, ... recall and access “on-the-go” makes data analysis even ... client feedback to assist in repository analytics and ...
(Date:4/28/2015)... 2015 Spartan Bioscience today announced that ... selected by the Ottawa Chamber of Commerce as one ... was selected from over 240 applicants based on his ... to Spartan, Dr. Lem founded Plexagen Diagnostics, and also ... holds a Medical Degree from the University of Ottawa, ...
(Date:4/27/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... year ended December 31, 2014. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... provide the outcome management and investors had hoped ... Therapeutics", said Andrew Rae , President & ...
Breaking Biology Technology:Novogen Regains Full Compliance with NASDAQ Listing Rule 2Novogen Regains Full Compliance with NASDAQ Listing Rule 3Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4
Cached News: